Normal Bone Mineral Content in Young Adults with Congenital Adrenal Hyperplasia due to 21-Hydroxylase DeficiencyChristiansen P.a · Mølgaard C.b,c · Müller J.a
aDepartment of Growth and Reproduction, Section GR-5064, Rigshospitalet, Copenhagen, bDepartment of Human Nutrition and Centre for Advanced Food Studies, Danish Veterinary and Agricultural University, Frederiksberg, and cPaediatric Nutrition Unit, The Juliane Marie Center, Rigshospitalet, Copenhagen, Denmark
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: To assess bone mineral content (BMC) and body composition in adolescents and young adults with congenital adrenal hyperplasia. Methods: BMC, anteroposterior-projected bone area (BA), bone mineral density, and fat mass percentage were determined by dual-energy X-ray absorptiometry in 18 patients aged 18–33 years (8 females and 10 males) with 21-hydroxylase deficiency using a Hologic QDR 1000/W densitometer. Results: BMC and bone mineral density for age were significantly reduced at –1.2 standard deviation scores (SDS; range from –2.8 to +4.1) and –1.1 SDS (range from –3.2 to +2.6), respectively. The BA for height was significantly increased at +1.7 SDS (range from –0.5 to +4.8), and the BMC for BA was normal at 0.3 SDS (range from –2.0 to +3.6). The median final height was significantly reduced at –1.6 SDS (range from –5.6 to +0.3), and the fat mass percentage was significantly increased at +1.5 SDS (range from –1.0 to +5.0). Conclusion: Our study population of young adults with 21-hydroxylase deficiency had a short stature and broad bones with a normal BMC and had an increased fat mass percentage.
© 2004 S. Karger AG, Basel
- Paganini C, Radetti G, Livieri C, Braga V, Migliavacca D, Adami S: Height, bone mineral density and bone markers in congenital adrenal hyperplasia. Horm Res 2000;54:164–168.
- Hagenfeldt K, Martin Ritzén E, Ringertz H, Helleday J, Carlström K: Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur J Endocrinol 2000;143:667–671.
Guo CY, Weetman AP, Eastell R: Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia: Clin Endocrinol (Oxf) 1996;45:535–541.
New MI, Gertner JM, Speiser PW, Del Balzo P: Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J Endocrinol Invest 1989;12(8 suppl 3):91–95.
- Cameron FJ, Kaymakci B, Byrt EA, Ebeling PR, Warne GL, Wark JD: Bone mineral density and body composition in congenital adrenal hyperplasia. J Clin Endocrinol Metab 1995;80:2238–2243.
- Young NR, Baker HW, Liu G, Seeman E: Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception (first of 2 parts). J Clin Endocrinol Metab 1993;77:1028–1032.
- Raisz LG, Kream BE: Regulation of bone formation. N Engl J Med 1983;309:29–35.
- Raisz LG, Kream BE: Regulation of bone formation (second of two parts). N Engl J Med 1983;309:83–89.
- Reid IR: Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 1989;30:83–103.
- Meunier PJ, Dempster DW, Edouard C, Chapuy, Arlot M, Charhon S: Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing’s syndrome. Adv Exp Med Biol 1984;171:191–200.
- Chong PK, Jung RT, Scrimgeour CM, Rennie MJ: The effect of pharmacological dosages of glucocorticoids on free living total energy expenditure in man. Clin Endocrinol (Oxf) 1994;40:577–581.
- Abad V, Chrousos GP, Reynolds JC, Nieman LK, Hill SC, Weinstein RS, Leong GM: Glucocorticoid excess during adolescence leads to a major persistent deficit in bone mass and an increase in central body fat. J Bone Miner Res 2001;16:1879–1885.
- Johnston CC Jr, Slemenda CW, Melton LJ 3rd: Clinical use of bone densitometry. N Engl J Med 1991;324:1105–1109.
- Lindsay R: Prevention and treatment of osteoporosis. Lancet 1993;341:801–805.
- Mølgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF: Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997;76:9–15.
- Andersen E, Hutchings B, Jansen J, Nyholm M: Heights and weights of Danish children. Ugeskr Laeger 1982;144:1760–1765.
- Nysom K, Holm K, Michaelsen KF, Hertz H, Müller J, Mølgaard C: Bone mass after treatment of malignant lymphoma in childhood. Med Pediatr Oncol 2001;37:518–524.
- Gussinyé M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibánez L, Yeste D: Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. Pediatrics 1997;100:671–674.
Mora S, Saggion F, Russo G, Weber G, Bellini A, Prinster C, Chiumello G: Bone density in young patients with congenital adrenal hyperplasia. Bone 1996;18:337–340.
- Jääskeläinen J, Voutilainen R: Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency. Clin Endocrinol (Oxf) 1996;45:707–713.
Speiser PW, New PI, Gertner JM: Increased bone mineral density in congenital adrenal hyperplasia (CAH). Pediatr Res 1993;33(suppl 5):81.
- Prentice A, Parsons TJ, Cole TJ: Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr 1994;60:837–842.
- Carter DR, Bouxsein ML, Marcus R: New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992;7:137–145.
- Girgis R, Winter JS: The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997;82:3926–3929.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.